Rationale: Insulin-like growth factor binding protein (IGFBP)-3 modulates vascular development by regulating endothelial progenitor cell (EPC) behavior, specifically stimulating EPC cell migration. This study was undertaken to investigate the mechanism of IGFBP-3 effects on EPC function and how IGFBP-3 mediates cytoprotection following vascular injury. Objective: To examine the mechanism of IGFBP-3-mediated repair following vascular injury. Methods and Results: We used 2 complementary vascular injury models: laser occlusion of retinal vessels in adult green fluorescent protein (GFP) chimeric mice and oxygen-induced retinopathy in mouse pups. Intravitreal injection of IGFBP-3-expressing plasmid into lasered GFP chimeric mice stimulated homing of EPCs, whereas reversing ischemia induced increases in macrophage infiltration. IGFBP-3 also reduced the retinal ceramide/ sphingomyelin ratio that was increased following laser injury. In the OIR model, IGFBP-3 prevented cell death of resident vascular endothelial cells and EPCs, while simultaneously increasing astrocytic ensheathment of vessels. For EPCs to orchestrate repair, these cells must migrate into ischemic tissue. This migratory ability is mediated, in part, by endogenous NO generation. Thus, we asked whether the migratory effects of IGFBP-3 were attributable to stimulation of NO generation. IGFBP-3 increased endothelial NO synthase expression in human EPCs leading to NO generation. IGFBP-3 exposure also led to the redistribution of vasodilator-stimulated phosphoprotein, an NO regulated protein critical for cell migration. IGFBP-3-mediated NO generation required high-density lipoprotein receptor activation and stimulation of phosphatidylinositol 3-kinase/Akt pathway. Conclusion: These studies support consideration of IGFBP-3 as a novel agent to restore the function of injured vasculature and restore NO generation. (Circ Res. 2009;105:897-905.)
I schemic tissues, by definition, require improved or greater oxygen delivery. Most pharmacological therapies of ischemic retinopathies try to inhibit pathological neovascularization but do not correct the underlying lack of blood supply. A more judicious approach would be to develop a pharmacological intervention to repair or create more normal vessels, thus converting ischemic tissue to nonischemic tissue. The insulin-like growth factor (IGF) system has been implicated in vascular physiology, including in the retina, because unregulated levels of IGF-1 can lead to inadequate vascularization, as well as pathological ocular neovascularization. [1] [2] [3] [4] [5] [6] The effects of IGF-1 are mediated by the IGF-1 receptor (IGF-1R) and modulated by complex interactions with six different IGF binding proteins (IGFBPs), which function not only as transporter proteins and storage pools for IGF-1 within tissues but also as signaling molecules. 7, 8 IGFBP-3 has IGF-1-independent effects and autocrine and paracrine actions affecting cell mobility and survival. 9, 10 Moreover, IGFBP-3 levels are increased by hypoxia. 5 Recently, we showed IGFBP-3 could serve as a modulator of vascular development by potently regulating bone marrow-derived cell (BMDC) function, specifically, stimulating endothelial precursors to differentiate into endothelial cells and promoting their migration. 11 Studies using the oxygeninduced retinopathy (OIR) model showed that IGFBP-3 prevented oxygen-induced vasoobliteration and vascular regression in vivo 11 (during phase 1 of the model) and subsequently mitigated preretinal neovascularization (phase 2 of the model). 10, 11 Lofqvist et al showed that IGFBP-3-deficient mice undergoing the OIR model have increased retinal vessel loss compared to wild type controls. 10 They also showed that premature infants with retinopathy of prematurity had lower serum levels of IGFBP-3 than infants with no retinopathy of prematurity, thus concluding that increased serum IGFBP-3 improved clinical outcome. These studies collectively support the role of IGFBP-3 as a critical regulator of vascular development.
In this study, we examined possible mechanism(s) by which IGFBP-3 modulated endothelial progenitor cell (EPC) behavior and mediated cytoprotection following vascular injury. For these studies, we used both in vitro systems and complementary in vivo vascular injury models: laser occlusion of retinal vessels in adult green fluorescent protein (GFP) chimeric mice and OIR in mouse pups. These 2 models were selected to examine the effects of IGFBP-3 on 2 distinct types of vasculature. The adult laser model represented the effects of IGFBP-3 on a stable vascular bed and the hyperoxia induced retinal injury model represented the effects of IGFBP-3 on an immature, unstable vascular bed, which was still undergoing active endothelial cell proliferation and migration. 12
Methods

Bone Marrow Transplantation Procedure
The care and use of animals is stated in the Online Data Supplemental material. The generation of the C57BL/6J.gfp chimeric mice was previously described. 13 
Laser Injury to Vessels to Induce Experimental Neovascularization
Two groups of C57BL/6J.gfp chimeric mice: laser only (nϭ15) and laser with IGFBP-3 injection (nϭ18) were subjected to laser injury in their right eye as previously described. 13 A third group of chimeric mice received only IGFBP-3 injection into their right eye (nϭ16).
The IGFBP-3 plasmid, under control of a proliferating endothelial cell-specific promoter, 14 was packaged into liposomes as previously described. 14 Immediately following laser treatment to the right eye, a total of 2 L of IGFBP-3 plasmid (2 g/L) packaged in liposomes was delivered intravitreally into the right eye of the appropriate groups.
OIR Model Studies
We used the OIR model developed by Smith et al. 15 Mice were intravitreally injected with 0.5 L (2 g/L) into one eye with either the IGFBP-3 plasmid or the cloning vector on postnatal day (P)1. Some animals were euthanized on removal from hyperoxia at P12, whereas others were euthanized at P17. At both time points, eyes from mice injected with the plasmid expressing IGFBP-3 (nϭ6) were compared to eyes from mice injected with empty cloning vector (nϭ6) or the noninjected eye of the same animal (nϭ6). Mice were euthanized, and eyes were enucleated and fixed for analysis as previously reported. 16 Details of immunohistochemistry procedures are given in the expanded Methods section in the Online Data Supplement, available at http://circres.ahajournals.org. 17
Lipid Analysis by Nanoelectrospray Ionization/Tandem Mass Spectrometry
Lipid species were detected using lipid class-specific precursor ion and neutral loss tandem mass spectrometry (MS/MS) scans as previously described 18, 19 and fatty acid constituents of individual lipid species were verified by product ion mode MS/MS in negative ion mode.
Refer to the supplemental methods section for details of the following studies: determination of NO production by DAF-FM fluorescence imaging, endothelial NO synthase (eNOS) activity, and in vitro functional studies in rat mesenteric and cerebral arteries.
Results
IGFBP-3 Promotes Retinal Vascular Repair by Increasing BMDC Homing Following Mechanical Disruption by Laser in GFP Chimeric Mice
In GFP chimeric mice receiving intravitreal injection of IGFBP-3 plasmid, GFP ϩ cells robustly participated in vascular remodeling ( Figure 1A through 1C), with GFP ϩ cells differentiating into endothelial cells (Online Figure I , A through I). Greater GFP ϩ cell incorporation was clearly evident in IGFBP-3 plasmid-injected eyes than in noninjected control eyes ( Figure 1A through 1C compared with Figure 1D through 1F). When the vasculature of GFP chimeric mice was injured by laser, significant numbers of circulating GFP ϩ cells took on the appearance of activated macrophages (Online Figure II) . In the animals receiving both laser and IGFBP-3 plasmid (Online Figure II , D through F), the distribution of GFP ϩ cells exhibited a similar vascular pattern, as seen with IGFBP-3 alone (Online Figure II , A through C), but the number of activated macrophages was greatly reduced compared to laser alone treated mice. We also confirmed by mRNA expression that intraocular injection of the IGFBP-3-expressing plasmid resulted in high IGFBP-3 mRNA levels in laser-treated mice for up to 1 week post laser injury (Online Figure III) . 
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IGFBP-3 Reduces Inflammation Following Laser Occlusion by Reducing the Retinal Ceramide/Sphingomyelin Ratio
Sphingolipids are lipid components of the membrane known to be highly expressed in the retina. The most abundant sphingolipid in the membrane, sphingomyelin, can be converted to ceramide under certain conditions, such as inflammation, and the ceramide/sphingomyelin ratio can be used as an indicator of the inflammatory/proapoptotic state. Laser treatment induced a 3.34-fold increase in ceramide/sphingomyelin ratio, consistent with proinflammatory and proapoptotic effects. IGFBP-3 returned ceramide/sphingomyelin ratio to control (untreated) levels ( Figure 2 ). We found no difference in ceramide/sphingomyelin levels in the IGFBP-3 only-injected animals (Online Figure IV , B) compared to controls (Online Figure IV , A). We analyzed another member of the sphingolipid family, sphingosine-1-phosphate (S1P). The levels of retinal S1P were low in all groups, and there was no difference between the groups, suggesting that any elevation of SIP following injury had returned to baseline levels by three weeks (data not shown).
IGFBP-3 Reversed Lipid Profile Changes Induced by Laser Occlusion
Because lipid peroxidation and lipid metabolism changes are highly associated with a number of retinal pathologies, we next addressed the effect of laser treatment on the structural component of retinal membranes, specifically membrane phospholipids. Laser treatment induced a significant increase in total retinal incorporation of docosahexaenoic acid (DHA) (22:6n3) into glycerophosphatidylcholine and glycerophosphatidylinositol. All glycerophosphatidylcholine and glycerophosphatidylinositol changes were completely reversed by IGFBP-3 treatment (Online Figures V and VI, respectively).
IGFBP-3 Reduces Endothelial Cell Death Following Hyperoxia-Induced Injury
We next used the OIR model, which exhibits extensive endothelial cell loss by apoptosis, to evaluate whether IGFBP-3 could mediate cytoprotection following injury by reducing cell death. We injected IGFBP-3 plasmid into the vitreous of mouse pups (P1) and then placed pups in hyperoxia on P7 for 5 days following the standard OIR model. The retinas of mice injected with IGFBP-3 had significantly reduced endothelial cell death ( Figure 
IGFBP-3 Increases Astrocytic Ensheathment of Neovasculature Following Hyperoxia-Induced Injury
We next asked whether IGFBP-3 could stabilize vessels during hyperoxia by increasing astrocytic ensheathment of retinal blood vessels. Compared with control plasmid-in- jected eyes ( Figure 4A through 4D), IGFBP-3-injected eyes led to astrocytes with far greater S-100/GFP immunoreactivity (shown as red in Figure 4E through 4H). The S-100 ensheathment of the underlying vasculature (shown as blue) was much more complete and the astrocytes had larger, thicker processes. Quantification of the frequency of astrocytic ensheathment showed that S-100 astrocytic ensheathment of retinal vasculature was significantly increased in both P12 ( Figure 4I and 4J) and P17 ( Figure 4K and 4L) IGFBP-3-injected eyes in comparison to control plasmidinjected eyes (PϽ0.05).
IGFBP-3 Generates NO via the Scavenger Receptor Class B, Type1
IGFBP-3 has both promitotic and proapoptotic effects. Such diverse biological effects can be mediated by activation of scavenger receptors. 20 -24 We asked whether IGFBP-3 may be initiating its vascular protective effect by binding to the scavenger receptor class B, type1 (SR-B1), which is the high-density lipoprotein (HDL) receptor. 25, 26 Activation of this receptor results in NO generation. 27 In human umbilical vein endothelial cells (HUVECs), IGFBP-3 at a physiological concentration (100 ng/mL) increased NO release as seen by an increase in DAF-FM fluorescence ( Figure 5 ). HDL at the physiological concentration of 1 mg/mL similarly increased NO generation, as did the combination of IGFBP-3 and HDL (PϽ0.05 for all treatments). In HUVECs, pretreatment with SR-B1 blocking antibody (SR-B1-Ab, 1:100) prevented NO release by IGFBP-3 (PϽ0.02) and, as expected, decreased the NO production in response to HDL (PϽ0.0001), as well as to the combination of both agents (PϽ0.01). Similar results were observed in human lung microvascular endothelial cells (HMVEC-L), whereas in the RGC-5 cells that do not express SR-B1, IGFBP-3-mediated NO release was not altered with coadministration of HDL and was not affected by the addition of SR-B1-Ab. IGFBP-3 increased NO production in human CD34 ϩ cells ( Figure 6 ), and in contrast to the response in HUVECs and HMVEC-L cells, the response to IGFBP-3 was greater than the response to HDL. When both agents were added simultaneously to CD34 ϩ cells, the response was intermediate, less than with IGFBP-3, but greater than with HDL ( Figure 6 ). We next confirmed the effect of IGFBP-3 on NO generation was attributable to increasing phosphorylation of eNOS at Ser1177 (Online Figure VII, A and B ) in human CD34 ϩ cells.
Our studies thus far show that IGFBP-3 stimulates NO release independent of HDL in 2 distinct endothelial cell types and in endothelial progenitors and that this effect is mediated by the SR-B1 receptor. To examine the signaling pathways by which SR-B1 activation by IGFBP-3 induces NO generation, we used selective pharmacological inhibitors to block phosphatidylinositol 3-kinase (PI3K) or Akt. IGFBP-3-mediated NO generation that was sensitive to blockade of SR-B1 or eNOS (by N-nitro-L-arginine methyl ester [L-NAME]) and was significantly decreased by either pretreatment with the PI3K inhibitor LY294002 (PϽ0.0001) or the Akt inhibitor triciribine (PϽ0.01) ( Figure 7A and 7B). We further confirmed these observations using a biochemical assay of eNOS activity involving determination of the conversion of L-arginine to L-citrulline in HUVECs. IGFBP-3 (100 ng/mL) stimulated eNOS activity was significantly reduced by pretreatment with SR-B1-Ab or LY294002 or triciribine (PϽ0.05) ( Figure 7C ). We next examined the effect of IGFBP-3 on phosphorylation of eNOS at Ser1177 in HUVECs. IGFBP-3 increased eNOS phosphorylation, which was blocked by pretreatment with SR-B1-Ab or triciribine significantly (Online Figure VIII) . These results support that IGFBP-3 induces eNOS activation and NO generation, which is dependent on the SR-B1-PI3K-Akt signaling pathway.
IGFBP-3 has also been shown to increase the activity of the sphingosine kinase (SphK)-1, the enzyme responsible for the generation of the potent angiogenic factor sphingosine-1phosphate (S1P). 7 Addition of the SphK inhibitor N,Ndimethylsphingosine resulted in a reduction in NO generation in response to IGFBP-3, as well as HDL, supporting that S1P generation was contributing to the effects of both HDL and IGFBP-3 on NO generation. CD34 ϩ cells, HUVECs, and HMVEC-L cells express S1P receptors, primarily S1P receptor 1, and express both SphK1 and SphK2 (Online Figure IX,  A and B ).
IGFBP-3 Causes Vasodilatation via SR-B1-Dependent NO Release
One of the primary functions of NO in the vasculature is to stimulate vasodilatation and numerous vascular protective agents stimulate NO generation. To determine whether IGFBP-3 mediates its protective effects by promoting NOmediated vasodilatation, we performed studies using intact arterial segments from 2 different vascular beds and assessed whether the NO released by IGFBP-3 produced a functional response in vitro. Rat mesenteric arterial segments (diameter, 276Ϯ11 m; nϭ12) preconstricted with phenylephrine were completely relaxed to carbachol, indicating the presence of functional endothelium. HDL (1 mg/mL) produced marked relaxation in the phenylephrine precontracted arteries. IGFBP-3 (100 ng/mL) produced a relaxant effect, however, weaker than HDL ( Figure 8A and 8B) . Phenylephrine precontraction was decreased by HDL and IGFBP-3 to 58Ϯ8% 
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(nϭ4; PϽ0.0001) and 81Ϯ7% (nϭ4; PϽ0.001) of the control, respectively. After IGFBP-3 treatment, addition of HDL resulted in an additional relaxation causing a total decrease in precontraction to 51Ϯ7% (nϭ3) ( Figure 8D) . Conversely, addition of IGFBP-3 after HDL treatment did not cause any further relaxation (data not shown). Furthermore, in a separate set of experiments, we observed IGFBP-3 did not produce any relaxation in arteries pretreated with L-NAME, a commonly used inhibitor of eNOS. (Figure 8C and 8D).
In another set of experiments, we pressurized rat posterior cerebral arteries (passive diameter, 175Ϯ5 m; nϭ15) in vitro at 70 mm Hg and evaluated the effect of IGFBP-3 on pressure induced constriction (decrease in intraluminal diameter) by applying it intraluminally. Pressurized arteries showed stable constriction in response to pressure and this constriction was significantly decreased by intraluminal IGFBP-3 (100 ng/mL). In the presence of intraluminal SR-B1-Ab or L-NAME, dilation by IGFBP-3 (decrease in constriction) was not observed ( Figure 8E ), suggesting that . IGFBP-3 increases astrocytic ensheathment of neovasculature following hyperoxia induced injury. In comparison to control (A through D), the S-100/GFAP ensheathment of underlying vasculature in the IGFBP-3-injected eyes (E through H) was much more complete and the astrocytes showed larger, thicker processes. I through L show representative fields of view from the mid-peripheral retina using a ϫ20 objective during normal development and during exposure to the OIR model. The ensheathment of GS lectin ϩ vascular endothelial cells (blue) by S-100 ϩ astrocytes (red) were determined. S-100 ensheathment of underlying vasculature in the IGFBP-3-injected eyes (J) was much more complete than in control injected eyes (I) at P12. S-100 ensheathment of underlying vasculature in the IGFBP-3-injected eyes (L) was much more complete than in control injected eyes (K) at P17. M, Astrocyte ensheathment of blood vessels was found to be more significant (PϽ0.05) in both P12 and P17 IGFBP-3-injected eyes in comparison to controls.
IGFBP-3 can cause arterial dilatation via SR-B1 dependent endothelial NO release in the arterial wall.
IGFBP-3-Mediated NO Generation Stimulates Vasodilator-Stimulated Phosphoprotein Redistribution
Previously, we demonstrated that a critical function of NO is to promote EPC migration by regulating the distribution of the cytoskeletal protein vasodilator-stimulated phosphoprotein (VASP). 17 VASP plays a pivotal role in promoting actin filament elongation at the leading edge of the cell by forming an active molecular motor complex that propels motility. Migration of BMDCs into areas of ischemia is paramount to their ability to initiate and orchestrate repair. 11 IGFBP-3stimulated migration was mediated by NO generation and blocked by the addition of the NO scavenger 2-(4carboxyphenol)-4,4,5,5-tetramethylimidazoline-1-oxyl-3oxide (data not shown). To examine this further, we asked whether treatment with IGFBP-3 resulted in redistribution of VASP. Compared to control conditions (Online Figure X, A) , IGFBP-3 treatment resulted in redistribution of to the lamellipodia VASP fluorescence to the periphery (Online Figure X,  C) , which was entirely eliminated by pretreatment with an NO scavenger (Online Figure X, E ).
Discussion
In this study, we identified cellular and signaling mechanisms responsible for the vascular protective effects of IGFBP-3. We examined the effects of IGFBP-3 on 2 distinct types of vasculature, a stable vascular bed (adult chimeric mice undergoing laser occlusion) and an immature, unstable vascular bed undergoing active endothelial cell proliferation and migration (the hyperoxia induced retinal injury model).
In the adult model, we show IGFBP-3 enhances repair by recruiting BMDCs to sites of laser occlusion within the ischemic retina. Even in the absence of retinal injury, overexpression of IGFBP-3 by the resident retinal endothelium promoted extravasation of BMDCs from the circulation into the perivascular region and their incorporation into areas of vascular remodeling. The reparative effects of IGFBP-3 are not limited to promoting BMDC homing, because IGFBP-3 reduced endothelial cell death and inflammation. During repair of the retina, IGFBP-3 increased astrocyte ensheathment, facilitating astrocyte-endothelial cell interactions, likely leading to enhanced barrier properties of the neovasculature and enhanced neuro-vascular coupling. Astrocytes serve as a template for both developmental and injury associated angiogenesis. 28 NO is an essential signaling molecule that promotes angiogenesis and regulates vascular tone and vascular remodeling. 29 Endogenous NO generation by BMDCs is critical for their migration, which in turn is required for their reparative function. IGFBP-3 increased eNOS phosphorylation, leading to increased NO generation and subsequent VASP redistribution promoting cell migration. Previously, we showed that IGFBP-3 promotes cell migration. 11 In this study, we showed that following IGFBP-3 treatment redistribution of VASP occurs to focal adhesions and pseudopodia, which we quantified (Online Figure X) . The rapid increase in VASP (within 15 minutes) suggests that VASP redistribution occurred, rather than a change in VASP protein expression.
Our studies support that SR-B1 mediates IGFBP-3-induced NO generation and that this occurs independent of HDL. Activation of eNOS by phosphorylation at Ser1177 by IGFBP-3 is dependent on activation of SR-B1 and the downstream signaling pathway involving P13K and Akt activity. We further show that SR-B1-dependent release of NO by IGFBP-3 modulates vascular reactivity in intact artery preparations from rat mesenteric and cerebral vascular beds resulting in decreased tone or dilation, and this effect is potentially vascular protective. Based on these studies, we postulate that SR-B1 activation by IGFBP-3 in the retinal vasculature generates NO, which is critical for vasodilatation, facilitating increased blood flow thereby infiltration of BMDCs to the sites of ischemia. NO released by IGFBP-3 in circulating EPCs and resident endothelial cells may modulate the function of BMDCs in an autocrine, as well as a paracrine manner hence, contributing to vascular repair.
In agreement with Granata et al in HUVECs, 7 our studies in CD34 ϩ cells support the notion that IGFBP-3-mediated NO generation is also dependent on activation of SphK1, because we observed that NO generation is blocked by SphK inhibition. S1P-mediated NO generation occurs by activation of endothelial differentiation gene receptors, also known as the S1P receptors. S1P, much like IGFBP-3, increases NO generation, thus promoting migration of cells. 30 Moreover, S1P, like IGFBP-3, has direct vascular protective effects. In the blood, S1P is associated with lipoproteins including low-density lipoprotein, very-low-density lipoprotein, and HDL, with the majority of S1P being bound to HDL. 31, 32 Our studies support that in EPCs, both IGFBP-3 and HDL activate SphK1, because inhibiting SphK1 with N,N-dimethylsphingosine resulted in loss of NO generation in response to either agents ( Figure 6 ).
Although we observed no increase in S1P in vivo in response to increase in IGFBP-3, we performed our measurements 3 weeks following retinal injury, and we suspect that any acute rise in S1P would have returned to baseline levels by this point. Despite our inability to detect S1P changes in the retina, we detected changes in other sphingolipids that persisted at 3 weeks. The laser-treated eyes had a higher ceramide/sphingomyelin ratio, consistent with an inflammatory, proapoptotic state. However, this increase in ceramide/ sphingomyelin ratio was completely normalized by IGFBP-3. This suggests IGFBP-3 mediates vascular protection through inhibition of inflammation, allowing IGFBP-3 to promote the recruitment of the reparative BMDC population, EPCs, rather than an inflammatory population. As observed in our studies using the adult laser injury model, IGFBP-3 reduces the number of inflammatory cells, specifically macrophages. We also found a striking increase in DHA-containing lysolipids in laser-treated eyes, indicating oxidative damage to the retina. These changes were completely normalized by increasing expression of IGFBP-3. In addition, there was an increase in DHA-containing phospholipids in laser-treated eyes, and IGFBP-3 treatment returned the phospholipid profile to normal levels, further supporting the role of IGFBP-3 in the repair of retinal vasculature.
Although this study has identified a new receptor system that mediates the effects of IGFBP-3 with respect to NO generation, IGFBP-3 has been shown to bind to several other receptors including the transforming growth factor-␤ receptor V, 33 transferrin receptor, 34 and low-density lipoprotein receptor-related protein (LRP). However when IGFBP-3 binds to LRP-1, it is degraded. 35 Hence, the diverse physiological effects of IGFBP-3 are likely to be mediated by distinct receptor systems.
In summary, our data support the hypothesis that IGFBP-3 mediates functional revascularization in the retina by promoting the homing of beneficial EPCs, while reducing the number of detrimental inflammatory cells, such as macrophages. Once EPCs are routed to areas of damage, IGFBP-3 enhances their incorporation and differentiation into endothelial cells, which facilitates vessel formation. 11 IGFBP-3 serves to protect the resident endothelium and EPC from cell death and increases astrocyte ensheathment to enhance vessel barrier properties and autoregulatory capacity. 36 Our studies suggest that these beneficial effects may be mediated by increased NO generation which occurs via IGFBP-3 binding of SR-B1 and subsequent activation of the P13K-Akt path-way. Our studies also support a second mechanism by which IGFBP-3 stimulates NO generation by activation of Sphk-1. We postulate that IGFBP-3 may modulate interactions between the scavenger receptor system and the S1P receptor system and may serve to regulate both physiological and pathological angiogenesis and vascular remodeling. Our findings support that IGFBP-3 in the circulation and in tissues may represent an endogenous vascular protective protein and following vascular injury increased levels of IGFBP-3 could promote proper revascularization. 
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None. Figure 8 . IGFBP-3 decreases arterial tone by increasing NO release in rat arteries. Representative tracings of tension (mN) developed (constriction) in wire-mounted rat mesenteric arterial segments to phenylephrine and the relaxation (dilatation) produced by 1 mg/mL HDL (A) and 100 ng/mL IGFBP-3 (B) with further additions of HDL and 10 mol/L carbachol. C, Pretreatment with L-NAME (100 mol/L) resulted in blockade of relaxation response to IGFBP-3. D, Summary of the effects of HDL and IGFBP-3 on constriction to phenylephrine. Data presented were percentages of constriction of phenylephrine. *PϽ0.001 compared to control. In the presence of L-NAME, no relaxation was observed with IGFBP-3. E, IGFBP-3 caused dilation of rat cerebral arteries by attenuating pressure-induced constriction at 70 mm Hg. Pressure-induced constriction, expressed as percentage decrease in the intraluminal diameter, was significantly decreased in the presence of intraluminal IGFBP-3 (100 ng/mL; *PϽ0.04), and this decrease was blocked when IGFBP-3 was applied with SR-B1 function blocking antibody (SR-B1-Ab) or 300 mol/L L-NAME.
